CA2450961A1 - Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition - Google Patents
Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition Download PDFInfo
- Publication number
- CA2450961A1 CA2450961A1 CA002450961A CA2450961A CA2450961A1 CA 2450961 A1 CA2450961 A1 CA 2450961A1 CA 002450961 A CA002450961 A CA 002450961A CA 2450961 A CA2450961 A CA 2450961A CA 2450961 A1 CA2450961 A1 CA 2450961A1
- Authority
- CA
- Canada
- Prior art keywords
- tiotropium bromide
- crystalline
- preparing
- pharmaceutical composition
- ang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Abstract
The invention relates to crystalline, water-free (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo [3.3.1.02,4] nonane-bromide, to a method for its production, and to the use thereof in the production of a drug, especially in the production of an anticholinergic drug.
Claims (12)
1) Anhydrous crystalline tiotropium bromide, characterised by a monoclinic elementary cell with the parameters a = 10.4336(2).ANG., b = 11.3297(3).ANG., c =
17.6332(4) .ANG., .alpha. = 90°, .beta. = 105.158(2)° and .lambda. = 90° (cell volume=2011.89(8).ANG.3) determined by X-ray structural analysis.
17.6332(4) .ANG., .alpha. = 90°, .beta. = 105.158(2)° and .lambda. = 90° (cell volume=2011.89(8).ANG.3) determined by X-ray structural analysis.
2) Process for preparing crystalline, anhydrous tiotropium bromide according to claim 1, characterised in that it is prepared by careful drying at more than 50°C, preferably at 60-100°C, under reduced pressure.
3) Process according to claim 2, characterised in that the drying is carried out over a period of from 15 minutes to 24 hours.
4) Process for preparing crystalline, anhydrous tiotropium bromide, according to claim 1, characterised in that it is prepared by storing crystalline tiotropium bromide monohydrate over a suitable drying agent for a period of 12 to 96 hours.
5) Crystalline anhydrous tiotropium bromide, obtainable according to one of claims 2, 3 or 4.
6) Use of crystalline tiotropium bromide monohydrate for preparing crystalline anhydrous tiotropium bromide.
7) Pharmaceutical composition, characterised in that it contains crystalline anhydrous tiotropium bromide according to one of claims 1 or 5.
8) Pharmaceutical composition according to claim 7, characterised in that it is an inhalable powder.
9) Inhalable powder according to claim 8, characterised in that it contains crystalline anhydrous tiotropium bromide according to claim 1 or 5 in admixture with a physiologically acceptable excipient.
10) Inhalable powder according to claim 9, characterised in that the excipient is selected from the group consisting of glucose and lactose.
11) Use of crystalline anhydrous tiotropium bromide according to one of claims 1 or 5 for preparing a pharmaceutical composition for the treatment of diseases in which the administration of an anticholinergic may have a therapeutic benefit.
12) Use according to claim 11, characterised in that the diseases are asthma or COPD.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129710.6 | 2001-06-22 | ||
| DE10129710 | 2001-06-22 | ||
| DE10215436 | 2002-04-08 | ||
| DE10215436.8 | 2002-04-08 | ||
| PCT/EP2002/006291 WO2003000265A1 (en) | 2001-06-22 | 2002-06-08 | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2450961A1 true CA2450961A1 (en) | 2003-01-03 |
| CA2450961C CA2450961C (en) | 2010-03-30 |
Family
ID=26009556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2450961A Expired - Fee Related CA2450961C (en) | 2001-06-22 | 2002-06-08 | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1401445B1 (en) |
| JP (1) | JP2005504015A (en) |
| KR (2) | KR100971616B1 (en) |
| CN (1) | CN100586948C (en) |
| AR (1) | AR037491A1 (en) |
| AT (1) | ATE337006T1 (en) |
| AU (1) | AU2002345016B2 (en) |
| BG (1) | BG66303B1 (en) |
| BR (1) | BR0210537A (en) |
| CA (1) | CA2450961C (en) |
| CO (1) | CO5550423A2 (en) |
| CY (1) | CY1105223T1 (en) |
| CZ (1) | CZ302786B6 (en) |
| DE (1) | DE50207943D1 (en) |
| DK (1) | DK1401445T3 (en) |
| EA (1) | EA005813B1 (en) |
| EE (1) | EE05316B1 (en) |
| EG (1) | EG24851A (en) |
| ES (1) | ES2271280T3 (en) |
| HK (1) | HK1068540A1 (en) |
| HR (1) | HRP20031066B1 (en) |
| HU (1) | HUP0400333A3 (en) |
| IL (2) | IL159238A0 (en) |
| ME (1) | ME00412B (en) |
| MX (1) | MXPA03011718A (en) |
| MY (1) | MY122779A (en) |
| NO (1) | NO334301B1 (en) |
| NZ (1) | NZ530690A (en) |
| PE (2) | PE20030130A1 (en) |
| PL (1) | PL208137B1 (en) |
| PT (1) | PT1401445E (en) |
| RS (1) | RS50441B (en) |
| SA (1) | SA02230255B1 (en) |
| SI (1) | SI1401445T1 (en) |
| SK (1) | SK287262B6 (en) |
| TW (2) | TWI261589B (en) |
| UY (1) | UY27342A1 (en) |
| WO (1) | WO2003000265A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651170A2 (en) * | 2003-07-31 | 2006-05-03 | Epigenesis Pharmaceuticals, Inc. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
| US7491719B2 (en) | 2004-05-14 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
| US7709474B2 (en) | 2006-08-22 | 2010-05-04 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, manufacturing and use thereof |
| US7727984B2 (en) | 2002-11-15 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US8394791B2 (en) | 2008-02-22 | 2013-03-12 | Boehringer Ingelheim International Gmbh | Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug |
| US8420809B2 (en) | 2005-08-15 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of betamimetics |
| US9108962B2 (en) | 2005-12-19 | 2015-08-18 | Sicor, Inc. | Forms of tiotropium bromide and processes for preparation thereof |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10212264A1 (en) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament |
| EP1682542B1 (en) * | 2003-11-03 | 2009-12-30 | Boehringer Ingelheim International GmbH | Novel crystalline anhydride with anticholinergic effect |
| DE102004016179A1 (en) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Compounds for the treatment of proliferative processes |
| NZ550797A (en) | 2004-04-22 | 2010-08-27 | Boehringer Ingelheim Int | Pharmaceutical combinations containing 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one for treating respiratory diseases |
| DE102004024454A1 (en) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel enantiomerically pure beta agonists, process for their preparation and their use as pharmaceuticals |
| EP1632229B1 (en) | 2004-08-11 | 2009-04-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Medicaments for the treatment of urinary tract disorders comprising anticholinergic agents |
| US20060079544A1 (en) * | 2004-08-13 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic |
| DE102004048389A1 (en) | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Modification of surfaces of lactose as adjuvant for use with powder inhalants |
| EA013239B1 (en) | 2005-04-28 | 2010-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Novel compounds for treating inflammatory diseases |
| RU2007144531A (en) * | 2005-05-02 | 2009-06-10 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | NEW CRYSTAL FORMS OF THIOTROPYBROMIDE |
| EP2085396A3 (en) * | 2005-05-02 | 2009-11-25 | Boehringer Ingelheim International Gmbh | Novel crystalline forms of tiotropium bromide |
| DE102005030733A1 (en) | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New drug combinations for the treatment of respiratory diseases containing long-acting beta-2 agonists and at least one other active ingredient |
| US20070086957A1 (en) | 2005-10-10 | 2007-04-19 | Thierry Bouyssou | Combination of medicaments for the treatment of respiratory diseases |
| EP1869035B2 (en) * | 2005-12-19 | 2015-08-12 | Sicor, Inc. | Novel crystalline form of tiotropium bromide and process for preparation thereof |
| CN100999521B (en) * | 2006-01-13 | 2010-12-08 | 江苏正大天晴药业股份有限公司 | Crystal anti-choline medicine thiatropic bromoammonium |
| BRPI0608387A2 (en) | 2006-04-19 | 2009-12-29 | Boehringer Ingelheim Int | compounds for the treatment of inflammatory diseases |
| EP1847543A1 (en) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| ES2360963T3 (en) | 2006-08-07 | 2011-06-10 | Boehringer Ingelheim International Gmbh | COMBINATIONS OF DRUGS FOR THE TREATMENT OF DISEASES OF THE RESPIRATORY ROUTES. |
| GB0716026D0 (en) | 2007-08-16 | 2007-09-26 | Norton Healthcare Ltd | An inhalable medicament |
| PT2610258E (en) | 2007-10-19 | 2014-10-24 | Boehringer Ingelheim Int | Substituted piperidino dihydrothieno pyrimidines |
| MX2011005150A (en) | 2008-12-19 | 2011-05-30 | Boehringer Ingelheim Int | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd. |
| WO2010101538A2 (en) | 2009-03-06 | 2010-09-10 | Bilgic Mahmut | New crystal forms |
| AP3170A (en) | 2009-12-17 | 2015-03-31 | Boehringer Ingelheim Int | New CCR2 receptor antagonists and uses thereof |
| WO2011073155A1 (en) | 2009-12-17 | 2011-06-23 | Boehringer Ingelheim International Gmbh | Novel antagonists for ccr2 and uses thereof |
| MX2012008533A (en) | 2010-01-29 | 2012-08-31 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors. |
| EP2569298B1 (en) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
| TR201007108A2 (en) * | 2010-08-25 | 2012-03-21 | B�Lg�� Mahmut | New tiotropium bromide crystal and production method. |
| JP5959537B2 (en) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Substituted pyridinyl-pyrimidines and their use as pharmaceuticals |
| TR201101897A2 (en) | 2011-02-28 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Crystal material containing tiotropium bromide |
| TR201102068A2 (en) | 2011-03-03 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Crystalline substances containing tiotropium bromide |
| TR201111589A2 (en) * | 2011-03-03 | 2012-09-21 | Bi̇lgi̇ç Mahmut | Tiotropium bromide anhydrous crystal form. |
| JP5786257B2 (en) | 2011-06-16 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel selective CCR2 antagonist |
| WO2013010839A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Novel and selective ccr2 antagonists |
| MX336224B (en) | 2011-07-26 | 2016-01-12 | Boehringer Ingelheim Int | Substituted quinolines and their use as medicaments. |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| PE20190180A1 (en) | 2011-11-25 | 2019-02-01 | Adverio Pharma Gmbh | PROCEDURE FOR THE PREPARATION OF 5-FLUORO-1H-PYRAZOLOPYRIDINES SUBSTITUTED |
| CZ304368B6 (en) | 2011-11-28 | 2014-04-02 | Zentiva, K.S. | Tiotropium bromide mixed solvate and process for preparing thereof |
| GB201200525D0 (en) | 2011-12-19 | 2012-02-29 | Teva Branded Pharmaceutical Prod R & D Inc | An inhalable medicament |
| PT106142B (en) * | 2012-02-10 | 2014-07-18 | Hovione Farmaci Ncia S A | PROCESS FOR THE PREPARATION OF TIOTROPE BROMIDE |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| EP2897955B1 (en) * | 2012-09-11 | 2019-11-06 | Bilgic, Mahmut | New tiotropium bromide crystalline form |
| PL2914593T3 (en) | 2012-11-05 | 2017-07-31 | Zentiva, K.S. | Stabilization of tiotropium solvates |
| CN104341412A (en) * | 2013-07-29 | 2015-02-11 | 天津金耀集团有限公司 | Anhydrous tiotropium bromide crystal preparation method |
| JP6599884B2 (en) | 2014-03-19 | 2019-10-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel heteroaryl compounds and their use as medicaments |
| US10034866B2 (en) | 2014-06-19 | 2018-07-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Inhalable medicament comprising tiotropium |
| EA035145B1 (en) | 2014-10-21 | 2020-05-06 | Ариад Фармасьютикалз, Инк. | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine |
| WO2017138896A1 (en) * | 2016-02-11 | 2017-08-17 | Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti | Crystalline form of tiotropium bromide anhydrate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931041C2 (en) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them |
| AU2002214996B2 (en) * | 2000-10-12 | 2007-03-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| DE10064816A1 (en) * | 2000-12-22 | 2002-06-27 | Boehringer Ingelheim Pharma | Production of tiotropium bromide useful as an anticholinergic comprises oxidation of di-(2-thienyl)-glycolic acid tropenol ester and subsequent quaternisation |
-
2002
- 2002-06-08 EE EEP200400029A patent/EE05316B1/en unknown
- 2002-06-08 ES ES02743165T patent/ES2271280T3/en not_active Expired - Lifetime
- 2002-06-08 HU HU0400333A patent/HUP0400333A3/en unknown
- 2002-06-08 CN CN02812303A patent/CN100586948C/en not_active Expired - Lifetime
- 2002-06-08 DE DE50207943T patent/DE50207943D1/en not_active Expired - Lifetime
- 2002-06-08 RS YUP-997/03A patent/RS50441B/en unknown
- 2002-06-08 MX MXPA03011718A patent/MXPA03011718A/en active IP Right Grant
- 2002-06-08 KR KR1020037016769A patent/KR100971616B1/en active IP Right Grant
- 2002-06-08 PL PL364489A patent/PL208137B1/en unknown
- 2002-06-08 NZ NZ530690A patent/NZ530690A/en not_active IP Right Cessation
- 2002-06-08 SK SK52-2004A patent/SK287262B6/en unknown
- 2002-06-08 SI SI200230431T patent/SI1401445T1/en unknown
- 2002-06-08 WO PCT/EP2002/006291 patent/WO2003000265A1/en active Application Filing
- 2002-06-08 ME MEP-2008-620A patent/ME00412B/en unknown
- 2002-06-08 DK DK02743165T patent/DK1401445T3/en active
- 2002-06-08 IL IL15923802A patent/IL159238A0/en unknown
- 2002-06-08 CA CA2450961A patent/CA2450961C/en not_active Expired - Fee Related
- 2002-06-08 KR KR1020097004823A patent/KR101011353B1/en active IP Right Grant
- 2002-06-08 AT AT02743165T patent/ATE337006T1/en active
- 2002-06-08 PT PT02743165T patent/PT1401445E/en unknown
- 2002-06-08 EA EA200301293A patent/EA005813B1/en not_active IP Right Cessation
- 2002-06-08 JP JP2003506910A patent/JP2005504015A/en active Pending
- 2002-06-08 BR BR0210537-3A patent/BR0210537A/en active Pending
- 2002-06-08 EP EP02743165A patent/EP1401445B1/en not_active Expired - Lifetime
- 2002-06-08 CZ CZ20040120A patent/CZ302786B6/en not_active IP Right Cessation
- 2002-06-08 AU AU2002345016A patent/AU2002345016B2/en not_active Expired
- 2002-06-19 TW TW091113373A patent/TWI261589B/en not_active IP Right Cessation
- 2002-06-19 EG EG2002060698A patent/EG24851A/en active
- 2002-06-19 TW TW095100968A patent/TW200617007A/en unknown
- 2002-06-20 UY UY27342A patent/UY27342A1/en not_active Application Discontinuation
- 2002-06-20 MY MYPI20022316A patent/MY122779A/en unknown
- 2002-06-21 AR ARP020102337A patent/AR037491A1/en not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 2002-06-21 PE PE2002000538A patent/PE20030130A1/en active IP Right Grant
- 2002-06-21 PE PE2007000660A patent/PE20081305A1/en not_active Application Discontinuation
- 2002-08-19 SA SA2230255A patent/SA02230255B1/en unknown
-
2003
- 2003-12-08 IL IL159238A patent/IL159238A/en active IP Right Grant
- 2003-12-12 BG BG108440A patent/BG66303B1/en active Active
- 2003-12-19 HR HR20031066A patent/HRP20031066B1/en not_active IP Right Cessation
- 2003-12-19 NO NO20035696A patent/NO334301B1/en not_active IP Right Cessation
-
2004
- 2004-01-20 CO CO04003764A patent/CO5550423A2/en not_active Application Discontinuation
-
2005
- 2005-01-29 HK HK05100780.9A patent/HK1068540A1/en not_active IP Right Cessation
-
2006
- 2006-09-20 CY CY20061101339T patent/CY1105223T1/en unknown
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7727984B2 (en) | 2002-11-15 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US7786111B2 (en) | 2002-11-15 | 2010-08-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US8044046B2 (en) | 2002-11-15 | 2011-10-25 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| EP1651170A2 (en) * | 2003-07-31 | 2006-05-03 | Epigenesis Pharmaceuticals, Inc. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| EP1651170A4 (en) * | 2003-07-31 | 2009-04-01 | Epigenesis Pharmaceuticals Inc | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US7491719B2 (en) | 2004-05-14 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
| US8034809B2 (en) | 2004-05-14 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| US8420809B2 (en) | 2005-08-15 | 2013-04-16 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of betamimetics |
| US7423146B2 (en) | 2005-11-09 | 2008-09-09 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of pharmaceutically active 3,1-benzoxazine-2-ones |
| US9108962B2 (en) | 2005-12-19 | 2015-08-18 | Sicor, Inc. | Forms of tiotropium bromide and processes for preparation thereof |
| US7709474B2 (en) | 2006-08-22 | 2010-05-04 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, manufacturing and use thereof |
| US8394791B2 (en) | 2008-02-22 | 2013-03-12 | Boehringer Ingelheim International Gmbh | Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2450961A1 (en) | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition | |
| US7078412B2 (en) | Quinuclidine derivatives and medicinal compositions containing the same | |
| US6433027B1 (en) | Medicament compositions based on tiotropium bromide and formoterol fumarate | |
| RU2325388C2 (en) | New anticholinergic preparations, method of their production and their application as pharmaceuticals | |
| US10597420B2 (en) | Derivatives of amphotericin B | |
| US20070208060A1 (en) | Compounds for treating inflammatory diseases | |
| US20040019073A1 (en) | Aerosol formulation for inhalation containing a tiotropium salt | |
| US20040266869A1 (en) | Novel medicament compositions based on anticholinesterase drugs and on ciclesonides | |
| US20040002548A1 (en) | Medicament compositions containing anticholinergically-effective compounds and betamimetics | |
| EP2091537B1 (en) | Pharmaceutical compositions for the treatment of capillary arteriopathy | |
| US20070167496A1 (en) | Roflumilast and glycopyrronium combination | |
| US20170202858A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| AU2003222791B2 (en) | Aerosol formulation for inhalation comprising a tiotropium salt | |
| KR20190010578A (en) | New Dapagliflozoline Crystal Forms and Methods of Making and Uses Thereof | |
| US20020193394A1 (en) | Compounds for treating inflammatory diseases | |
| US20110224249A1 (en) | Novel Hydrate Form | |
| MXPA05005443A (en) | Carbamic acid esters with an anticholinergic action. | |
| EP2566449B1 (en) | Pharmaceutical compositions comprising ceftibuten | |
| CA2544432A1 (en) | Stable pharmaceutical composition comprising granulocyte-colony stimulating factor | |
| US7381733B2 (en) | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases | |
| KR20090024248A (en) | Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders | |
| CA2043107A1 (en) | Therapeutic compound | |
| CA2456721A1 (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| NZ536282A (en) | Aerosol formulation for inhalation comprising a tiotropium salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |